2022 forecast: AI, Fintiv rule, Arthrex
In the third part of WIPR’s forecast series, leading lawyers offer their views on, what lies ahead for artificial intelligence in the IP landscape, and the beleaguered Patent Trial and Appeal Board’s (PTAB) likely future stance on the NHK-Fintiv rule and Arthrex-related requests for inter partes reviews of patents.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk